What is a stock summary page? Click here for an overview.
Business Description
NovMetaPharma Co Ltd
ISIN : KR7229500004
Compare
Compare
Traded in other countries / regions
229500.Korea IPO Date
2015-10-28Description
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.07 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -5.96 | |||||
| Beneish M-Score | -1.58 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -21.1 | |||||
| 3-Year EBITDA Growth Rate | 15.7 | |||||
| 3-Year EPS without NRI Growth Rate | 12.1 | |||||
| 3-Year FCF Growth Rate | 5.3 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 5.42 | |||||
| 9-Day RSI | 22.14 | |||||
| 14-Day RSI | 35.49 | |||||
| 3-1 Month Momentum % | 38.5 | |||||
| 6-1 Month Momentum % | 53.26 | |||||
| 12-1 Month Momentum % | -63.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.62 | |||||
| Quick Ratio | 0.62 | |||||
| Cash Ratio | 0.52 | |||||
| Days Inventory | 290.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.1 | |||||
| Shareholder Yield % | -1.05 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.72 | |||||
| Operating Margin % | -12226.75 | |||||
| Net Margin % | -12368.2 | |||||
| FCF Margin % | -11409.29 | |||||
| ROE % | -152.95 | |||||
| ROA % | -80.44 | |||||
| ROIC % | -97.64 | |||||
| 3-Year ROIIC % | -28.44 | |||||
| ROC (Joel Greenblatt) % | -1778.93 | |||||
| ROCE % | -134.07 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1754.59 | |||||
| PB Ratio | 46.04 | |||||
| Price-to-Tangible-Book | 391.78 | |||||
| EV-to-EBIT | -15.29 | |||||
| EV-to-EBITDA | -16.09 | |||||
| EV-to-Revenue | 1888.47 | |||||
| EV-to-FCF | -19.67 | |||||
| Price-to-GF-Value | 0.43 | |||||
| Earnings Yield (Greenblatt) % | -6.53 | |||||
| FCF Yield % | -5.97 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NovMetaPharma Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 45.315 | ||
| EPS (TTM) (â‚©) | -504 | ||
| Beta | 0.55 | ||
| 3-Year Sharpe Ratio | 0.14 | ||
| 3-Year Sortino Ratio | 0.26 | ||
| Volatility % | 121.34 | ||
| 14-Day RSI | 35.49 | ||
| 14-Day ATR (â‚©) | 645.624955 | ||
| 20-Day SMA (â‚©) | 9014.5 | ||
| 12-1 Month Momentum % | -63.85 | ||
| 52-Week Range (â‚©) | 4505 - 20500 | ||
| Shares Outstanding (Mil) | 12.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NovMetaPharma Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NovMetaPharma Co Ltd Stock Events
| Event | Date | Price (â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
NovMetaPharma Co Ltd Frequently Asked Questions
What is NovMetaPharma Co Ltd(XKRX:229500)'s stock price today?
The current price of XKRX:229500 is â‚©7150.00. The 52 week high of XKRX:229500 is â‚©20500.00 and 52 week low is â‚©4505.00.
When is next earnings date of NovMetaPharma Co Ltd(XKRX:229500)?
The next earnings date of NovMetaPharma Co Ltd(XKRX:229500) is .
Does NovMetaPharma Co Ltd(XKRX:229500) pay dividends? If so, how much?
NovMetaPharma Co Ltd(XKRX:229500) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers